Revolution Medicines Stock
Clinical-stage oncology therapeutics company
Sign up today and learn more about Revolution Medicines Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Revolution Medicines Stock
REVOLUTION Medicines is a clinical-stage company involved in the discovery and development of precise small molecule therapeutics designed to translate frontier oncology targets within notorious pathways to outsmart cancer. It possesses oncology drug discovery capabilities built upon scientific knowledge of the biology of cancer pathways and proprietary technologies that enable the creation of small molecules that target atypical drug binding sites.
Funding History
| February 2015 | $45.0M |
|---|---|
| December 2016 | $25.0M |
| April 2018 | $56.0M |
| July 2019 | $100M |
Management
Senior Vice President Human Resources
Luan M. Wilfong
Co-founder and Chief Scientific Officer
David L. Pompliano
CFO
Ryan Martins
Chief Operating Officer
Margaret Horn
SVP Clinical Development
Xiaolin Wang
Founding President & Chief Executive Officer
Mark A. Goldsmith
Founder & Scientific Advisory Board Chairman
Martin D. Burke
President of Research and Development
Steve Kelsey
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
